Precigen Receives Orphan Drug Designation for PRGN-2012 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission
– Designation is an important step toward bringing this potentially life-changing therapy to European patients –
– EU Orphan Drug Designation is the first regulatory designation for a gorilla adenovector based immunotherapy outside of the United States for the Company –
Related news for (PGEN)
- Precigen Announces Long-Term Follow-Up Results Highlighting Ongoing Durable Complete Responses after Treatment with PAPZIMEOS, the First and Only FDA-approved Therapy for Adults with Recurrent Respiratory Papillomatosis
- Precigen Announces Up to $125 Million Non-Dilutive Financing
- Biotech Rally Builds as Markets Eye Buybacks and Breakouts
- Biotech Closing Strong, Set for After-Hours Surprises as Momentum Builds
- Don’t Miss Out: MoBot’s Latest Stock Updates 08/21/25 10:00 AM